lowtrade

[Golden Cross]

$RGBP .0275 Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

Regen BioPharma Website:
https://www.regenbiopharmainc.com/

RGBP IHUB Page:
https://investorshub.advfn.com/Regen-BioPharma-Inc-RGBP-28863/